Skip to main content

GoodRx Holdings, Inc. (GDRX)

Computer Software and Services Information Technology
Stock AI

Financial Metrics

Price to Earnings75.37x
Revenue Growth (1Y)-1.83%
Debt to Equity0.76x

Strengths

Stock Chart

Valuation

GoodRx Holdings, Inc. is overvalued

News

All
Press Releases
News
Filings
GoodRx Reports Second Quarter 2026 Results
August 05, 2026GoodRx Reports Second Quarter 2026 Results
10-Q Quarterly Report for 2026 Q2
August 05, 202610-Q Quarterly Report for 2026 Q2

GoodRx Announces Date for Second Quarter 2026 Earnings Release and Conference Call
July 09, 2026 GoodRx Announces Date for Second Quarter 2026 Earnings Release and Conference Call
GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs
May 27, 2026GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs
GoodRx Reports First Quarter 2026 Results
May 06, 2026GoodRx Reports First Quarter 2026 Results
10-Q Quarterly Report for 2026 Q1
May 06, 202610-Q Quarterly Report for 2026 Q1
GoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes Patients
May 01, 2026GoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes Patients
GoodRx Announces Date for First Quarter 2026 Earnings Release and Conference Call
April 17, 2026GoodRx Announces Date for First Quarter 2026 Earnings Release and Conference Call
GoodRx Rallies As Wegovy HD Rollout Targets Self-Pay Market
April 15, 2026GoodRx Rallies As Wegovy HD Rollout Targets Self-Pay Market
GoodRx Now Offers Access to Wegovy® HD at $399 Per Month Self-Pay Price
April 15, 2026GoodRx Now Offers Access to Wegovy® HD at $399 Per Month Self-Pay Price
GoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide
April 09, 2026GoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide
GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications
March 11, 2026GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications
10-K Annual Report for 2025 FY
February 26, 202610-K Annual Report for 2025 FY
GoodRx Reports Fourth Quarter and Full Year 2025 Results
February 25, 2026GoodRx Reports Fourth Quarter and Full Year 2025 Results
GoodRx Expands Into Employer Market With Launch of “GoodRx Employer Direct”
February 24, 2026GoodRx Expands Into Employer Market With Launch of “GoodRx Employer Direct”
GoodRx Powers Pricing for Leading Brand Medications on TrumpRx
February 06, 2026GoodRx Powers Pricing for Leading Brand Medications on TrumpRx
GoodRx Earns HITRUST i1 Certification for the Second Consecutive Year, Reinforcing Its Commitment to Protecting Healthcare Data at Scale
February 02, 2026GoodRx Earns HITRUST i1 Certification for the Second Consecutive Year, Reinforcing Its Commitment to Protecting Healthcare Data at Scale

GoodRx Announces Date for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call
January 28, 2026 GoodRx Announces Date for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call
Surescripts and GoodRx Partner to Advance Patient Price Transparency
January 13, 2026Surescripts and GoodRx Partner to Advance Patient Price Transparency
GoodRx Launches RxSmartSaver at Giant Eagle Pharmacies
January 08, 2026GoodRx Launches RxSmartSaver at Giant Eagle Pharmacies
Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting Cost
January 05, 2026Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting Cost
GoodRx Now Offers Novo Nordisk’s Cash Price for the Launch of the Wegovy® Pill
January 05, 2026GoodRx Now Offers Novo Nordisk’s Cash Price for the Launch of the Wegovy® Pill

GoodRx to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 16, 2025 GoodRx to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Novo Nordisk Leans Into Affordability Amid Rising Competition
November 17, 2025Novo Nordisk Leans Into Affordability Amid Rising Competition
GoodRx Launches New $39 Per Month Weight Loss Telemedicine Subscription, Unveils Industry-Leading Introductory Cash Price of $199 Per Month for Ozempic® and Wegovy®
November 17, 2025GoodRx Launches New $39 Per Month Weight Loss Telemedicine Subscription, Unveils Industry-Leading Introductory Cash Price of $199 Per Month for Ozempic® and Wegovy®
GoodRx Reports Third Quarter 2025 Results
November 04, 2025GoodRx Reports Third Quarter 2025 Results
10-Q Quarterly Report for 2025 Q3
November 04, 202510-Q Quarterly Report for 2025 Q3
GoodRx Launches New Hair Loss Subscription for Men to Simplify Access to Affordable Treatment
October 15, 2025GoodRx Launches New Hair Loss Subscription for Men to Simplify Access to Affordable Treatment
Trump Administration Engages Pharmacies, GoodRx For TrumpRx Launch
October 09, 2025Trump Administration Engages Pharmacies, GoodRx For TrumpRx Launch

GoodRx Announces Date for Third Quarter 2025 Earnings Release and Conference Call
October 08, 2025 GoodRx Announces Date for Third Quarter 2025 Earnings Release and Conference Call
GoodRx Expands Affordable Access to Repatha® with Nearly 60% Savings
October 06, 2025GoodRx Expands Affordable Access to Repatha® with Nearly 60% Savings
GoodRx Launches Brand Medication Savings Program at National Retail Pharmacy
October 01, 2025GoodRx Launches Brand Medication Savings Program at National Retail Pharmacy
GoodRx Saddles Up With “The Savings Wrangler,” a Bold New Brand Campaign to Tame the Wild West of Prescription Pricing
September 02, 2025GoodRx Saddles Up With “The Savings Wrangler,” a Bold New Brand Campaign to Tame the Wild West of Prescription Pricing
What's Going On With Hims & Hers Shares Today?
August 19, 2025What's Going On With Hims & Hers Shares Today?
Ozempic Gains First Approval In Canada For Kidney Disease And Cardiovascular Death Risk
August 19, 2025Ozempic Gains First Approval In Canada For Kidney Disease And Cardiovascular Death Risk
GoodRx Holdings Surges 5% After Hours on Novo Nordisk Partnership for $499 Monthly Ozempic, Wegovy Access
August 19, 2025GoodRx Holdings Surges 5% After Hours on Novo Nordisk Partnership for $499 Monthly Ozempic, Wegovy Access
Intel, Palo Alto Networks, Goodrx, Applied Digital And Duolingo: Why These 5 Stocks Are On Investors' Radars Today
August 19, 2025Intel, Palo Alto Networks, Goodrx, Applied Digital And Duolingo: Why These 5 Stocks Are On Investors' Radars Today
Stocks Muted Ahead Trump-Zelenskyy Meeting, First Solar Jumps: What's Moving Markets Monday?
August 18, 2025Stocks Muted Ahead Trump-Zelenskyy Meeting, First Solar Jumps: What's Moving Markets Monday?
Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August
August 18, 2025Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August
Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock Skyrockets
August 18, 2025Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock Skyrockets
GoodRx Announces Collaboration with Novo Nordisk to Expand Access to Ozempic® and Wegovy® for $499-Per-Month
August 18, 2025GoodRx Announces Collaboration with Novo Nordisk to Expand Access to Ozempic® and Wegovy® for $499-Per-Month
GoodRx Reports Second Quarter 2025 Results
August 06, 2025GoodRx Reports Second Quarter 2025 Results
10-Q Quarterly Report for 2025 Q2
August 06, 202510-Q Quarterly Report for 2025 Q2
GoodRx Appoints Amazon Pharmacy Veteran Laura Jensen as President of Pharma Solutions
July 28, 2025GoodRx Appoints Amazon Pharmacy Veteran Laura Jensen as President of Pharma Solutions

GOODRX INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of GoodRx Holdings, Inc. - GDRX
July 18, 2025 GOODRX INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of GoodRx Holdings, Inc. - GDRX

GoodRx Announces Date for Second Quarter 2025 Earnings Release and Conference Call
July 09, 2025 GoodRx Announces Date for Second Quarter 2025 Earnings Release and Conference Call
10-Q Quarterly Report for 2025 Q1
May 07, 202510-Q Quarterly Report for 2025 Q1
GoodRx Reports Mixed Q4: Pharma Strength Amid Subscription Decline, Sluggish Prescription Sales
February 27, 2025GoodRx Reports Mixed Q4: Pharma Strength Amid Subscription Decline, Sluggish Prescription Sales
10-K Annual Report for 2024 FY
February 27, 202510-K Annual Report for 2024 FY
10-Q Quarterly Report for 2024 Q3
November 07, 202410-Q Quarterly Report for 2024 Q3
10-Q Quarterly Report for 2024 Q2
August 08, 202410-Q Quarterly Report for 2024 Q2
10-Q Quarterly Report for 2024 Q1
May 09, 202410-Q Quarterly Report for 2024 Q1
10-K Annual Report for 2023 FY
February 29, 202410-K Annual Report for 2023 FY
10-Q Quarterly Report for 2023 Q3
November 09, 202310-Q Quarterly Report for 2023 Q3
10-Q Quarterly Report for 2023 Q2
August 09, 202310-Q Quarterly Report for 2023 Q2
10-Q Quarterly Report for 2023 Q1
May 10, 202310-Q Quarterly Report for 2023 Q1
10-K Annual Report for 2022 FY
March 01, 202310-K Annual Report for 2022 FY
10-Q Quarterly Report for 2022 Q3
November 09, 202210-Q Quarterly Report for 2022 Q3
10-Q Quarterly Report for 2022 Q2
August 09, 202210-Q Quarterly Report for 2022 Q2
10-Q Quarterly Report for 2022 Q1
May 10, 202210-Q Quarterly Report for 2022 Q1
10-K Annual Report for 2021 FY
March 01, 202210-K Annual Report for 2021 FY
10-Q Quarterly Report for 2021 Q3
November 12, 202110-Q Quarterly Report for 2021 Q3

A. Company Overview

GoodRx Holdings, Inc. is a healthcare technology company focused on enhancing the affordability and accessibility of healthcare services for consumers in the United States. Founded with the mission to assist Americans in obtaining necessary healthcare at a reasonable price, the company has developed a comprehensive, consumer-oriented digital platform. Initially starting as a price comparison tool for prescription medications, GoodRx has significantly expanded its offerings to include various healthcare services, telehealth solutions, and wellness-related content.

The company's platform processes a staggering volume of pricing data—over 320 billion pricing data points daily—integrating this information into a user-friendly interface that enables users to access geographically relevant prescription pricing. This system provides substantial savings on medications through negotiated prices, enabling consumers to utilize GoodRx codes at pharmacies nationwide. GoodRx has positioned itself as not only a cost-saving resource for consumers but also as a tool for improving overall health outcomes by increasing medication adherence and enabling quicker access to necessary treatments.

B. Industry Challenges

The U.S. healthcare market, valued at approximately $4.5 trillion, is characterized by significant consumer challenges, including a lack of transparency and fragmentation. Simple transactions such as filling prescriptions or finding affordable healthcare services are often complicated. Variabilities in medication pricing across pharmacies, coupled with a complex reimbursement landscape, contribute to consumer confusion and economic strain. GoodRx addresses this opacity by providing straightforward, accessible solutions that facilitate consumer engagement and empower informed healthcare decisions.

C. Market Opportunity

As consumers become increasingly cost-aware and informed, there is a growing market opportunity for platforms that enable transparent healthcare transactions. GoodRx estimates its total addressable market (TAM) between $534 billion and $607 billion, covering a broad spectrum of prescription opportunities. This includes approximately $515 billion to $588 billion specifically for prescriptions, and a $19 billion opportunity for solutions targeted at pharmaceutical manufacturers. By leveraging technology to present consumers with comprehensive data, GoodRx aims to streamline the healthcare purchasing process and enhance consumer efficiency.

D. Value Proposition

GoodRx creates significant value for multiple stakeholders in the healthcare ecosystem, including consumers, healthcare providers, pharmacy benefit managers (PBMs), pharmacies, and pharmaceutical manufacturers.

  • Consumers: The platform offers various mobile-first solutions that help simplify and reduce healthcare costs, enhancing medication adherence and improving health outcomes.
  • Healthcare Professionals: GoodRx empowers physicians by facilitating better patient engagement with price transparency and medication adherence support. Its provider tools integrate directly into electronic health record (EHR) systems, providing healthcare professionals with real-time pricing to enhance patient care.
  • Healthcare Companies: PBMs and pharmacies benefit from increased traffic to their services through GoodRx's consumer platforms. The tool enhances market outreach and accessibility to their affordability solutions.

E. Offerings

GoodRx's offerings can be categorized into several key areas:

Prescription Marketplace

The cornerstone of GoodRx's service is its prescription marketplace, which includes:

  • Prescription Transactions Offering: This feature aggregates pricing data from a multitude of sources, providing consumers with curated pricing information and enabling them to save significantly on medications. The platform maintains a high frequency of data updates and competitive pricing.
  • Subscription Offerings: GoodRx Gold provides subscribers access to even lower prices, along with benefits like home delivery and telehealth services, enhancing consumer value without additional costs.

Pharma Manufacturer Solutions

GoodRx collaborates with pharmaceutical manufacturers to integrate affordability solutions (e.g., co-pay cards, patient assistance programs) into its platform, enhancing access for consumers while generating additional revenue through partnerships.

F. Growth Strategy

GoodRx's growth strategy entails several critical elements aimed at expanding its consumer base and enhancing its offerings:

  • Consumer Acquisition: Continuous promotion of its existing offerings to attract new users, alongside efforts to improve brand awareness and education regarding prescription pricing.
  • Monetization Channel Diversification: Encouraging existing consumers to engage with multiple GoodRx offerings to enhance satisfaction and lifetime value.
  • Investment in Product Development: Committing resources to expand and enhance existing solutions, focusing on convenience and affordability for consumers.
  • Strategic Partnerships and Acquisitions: Seeking relationships and partnerships across the healthcare ecosystem to amplify service offerings, and integrating innovative solutions that enhance consumer engagement.

G. Competition and Industry Participants

The competitive landscape for GoodRx is diverse, encompassing a range of both large and small organizations that provide similar prescription savings solutions. As the industry undergoes further consolidation, maintaining favorable agreements with PBMs and competing effectively against established players remains a priority for GoodRx.

H. Intellectual Property

GoodRx relies on a robust framework of intellectual property protections, including trademarks and patents, to shield its unique platform and offerings. The proprietary technology and data integration capabilities are key to its market position, enabling the company to offer a distinctive value proposition compared to competitors.

I. Philanthropy

The company actively engages in philanthropic initiatives through its "Good To Give" program, supporting numerous nonprofit organizations and encouraging employee participation in community service. Such efforts are part of GoodRx's broader commitment to corporate social responsibility and community engagement.

J. People and Culture

As a rapidly growing organization, GoodRx prioritizes its workforce, emphasizing a culture rooted in trust, empathy, and support. The company offers robust benefits and opportunities for professional development, cultivating an inclusive workplace environment across its operations.

Stock Infos

SectorInformation Technology
IndustryComputer Software and Services
CEOScott Wagner

Dividends

Copyright ©2026 Taurigo GmbH. All rights reserved.Taurigo GmbH provides no investment advice. Any analyses, research, ideas, prices, or other information contained on this website are provided as general market information for educational and entertainment purposes only, and do not constitute investment advice. We assume no responsibility for the accuracy, completeness or timeliness of any financial information contained on this site. In particular, we do not constitute an invitation to buy, sell or hold securities or other financial products. We shall not be liable for any loss or damage, including without limitation loss of profits, arising directly or indirectly from use of or reliance on the provided information. Before making any investment decision, you should consider whether it is suitable for your situation and obtain appropriate financial, tax and legal advice.